Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
Guardant Health, Inc. reported insider equity transactions by its Chief Technology Officer, Darya Chudova, on Form 4. On 12/08/2025, 68,144 shares of common stock were transferred at no cost from her direct ownership to the Chudova Family Trust, changing the form of ownership from direct to indirect. The filing also shows two open-market sales of Guardant Health common stock on the same date: 9,271 shares sold at a weighted average price of $106.0029 per share and 13,664 shares sold at a weighted average price of $105.0371 per share, executed in multiple transactions within narrow price ranges.
After these transactions, Chudova reported beneficial ownership of 21,734 shares held directly and 54,480 shares held indirectly through the Chudova Family Trust. The disclosure notes that 488 of the shares in Table I were previously acquired under Guardant Health's Employee Stock Purchase Plan.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported a series of open-market sales of the company’s common stock on December 5, 2025. The Form 4 shows multiple sale transactions at weighted average prices including $101.4027, $102.0946, $103.2528, $103.9717, $105.9863 and $106.7081 per share, with each line representing shares sold across narrower intraday price ranges from $100.710 up to $106.990 per share. Each transaction is coded as a sale and reported as directly held. Following these sales, Freeman’s directly owned position in Guardant Health common stock is disclosed as 25,987 shares.
Guardant Health (GH) director Roberto A. Mignone reported an equity transaction involving restricted stock units and common stock. On 11/21/2025, 264 restricted stock units were converted into 264 shares of common stock at an exercise price of $0, reported under transaction code M.
Following this transaction, Mignone beneficially owned 3,431 shares of Guardant Health common stock directly and 9,240 restricted stock units. The RSU award was granted on November 8, 2024 and vests over four years: 25% of the shares vested on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) director reports small stock sale
A director of Guardant Health, Inc., identified in the signature as Musa Tariq, reported selling 116 shares of the company’s common stock on 11/19/2025. The sale, coded as an "S" transaction, was executed at a price of $96.25 per share. After this transaction, the reporting person beneficially owns 7,859 shares of Guardant Health common stock, held in direct ownership.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported an equity award vesting and share issuance. On 11/17/2025, 232 restricted stock units converted into 232 shares of common stock at an exercise price of $0, increasing his directly held common stock to 1,047 shares.
The transaction reflects ongoing vesting from a restricted stock unit grant awarded on July 17, 2024. That grant vests over four years, with 25% of the shares vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting in equal monthly installments over the following three years. After this conversion, he continues to hold 7,425 restricted stock units directly.
Guardant Health, Inc. (GH)Common Stock were acquired at a price of $0, following the vesting and settlement of a previously granted restricted stock unit award. After this transaction, Tariq beneficially owned 7,975 shares of Common Stock directly and held 3,998 restricted stock units directly.
The restricted stock units were granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the subsequent three-year period.
Guardant Health (GH) reported insider activity by director Manuel Hidalgo Medina. On 11/07/2025, he exercised 1,000 stock options at $32.55 and sold 1,500 shares in two trades at $95.1651 and $95.2301. Following these transactions, he held 815 shares directly.
The exercised option was granted on July 17, 2024 and expires on July 17, 2034. Per the award’s terms, 25% vested on the one-year anniversary of July 17, 2024, with the remaining 75% vesting monthly over the next three years. After these transactions, he reported 16,029 derivative securities (stock options) beneficially owned.
Guardant Health (GH) reported an insider transaction by its Chief Legal Officer. On 11/07/2025, the reporting person sold 8,996 shares of common stock at a price of $96.25 per share. Following the sale, the filing shows 43,172 shares beneficially owned, held directly.
Guardant Health completed two financings. It sold 3,833,332 shares of common stock at $90.00 per share, including the full 499,999-share option, for net proceeds of approximately $327.2 million after underwriting discounts and expenses. The equity sale was made off an effective shelf and closed on November 7, 2025.
Separately, the company issued $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due May 15, 2033, including the full $52.5 million option. Net proceeds were approximately $390.0 million. The notes carry no regular interest, are unsecured, and are convertible at an initial rate of 8.2305 shares per $1,000 (initial conversion price about $121.50 per share), a premium of about
Guardant Health (GH) is offering 3,333,333 shares of common stock at $90.00 per share, for estimated net proceeds of about $284.4 million after fees and expenses. The underwriters have a 30‑day option to buy up to 499,999 additional shares. Shares outstanding are expected to be 128,339,048 immediately after this offering (or 128,839,047 if the option is fully exercised).
Concurrently, the company is offering 0% Convertible Senior Notes due 2033 in an aggregate principal amount of $350.0 million (or $402.5 million if the option is exercised) in a separate, exempt offering; neither transaction is contingent on the other. Guardant plans to use equity and, if completed, note proceeds for general corporate purposes, which may include repurchasing a portion of its 2027 notes.
The stock trades on Nasdaq as “GH”; the last reported sale price on November 4, 2025 was $98.14. Settlement is expected on or about November 7, 2025 (T+2).